Brivanib Exhibits Potential for Pharmacokinetic Drug–Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes-Reference-Cited by-同舟云学术

Brivanib Exhibits Potential for Pharmacokinetic Drug–Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes

Published:2019-10-21 Issue:11 Volume:16 Page:4436-4450
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Hofman Jakub¹^ORCID,Sorf Ales¹,Vagiannis Dimitrios¹,Sucha Simona¹^ORCID,Kammerer Sarah²,Küpper Jan-Heiner²,Chen Si³,Guo Lei³,Ceckova Martina¹,Staud Frantisek¹

Affiliation:

1. Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic

2. Institute of Biotechnology, Brandenburg University of Technology Cottbus-Senftenberg, Universitätsplatz 1, 01968 Senftenberg, Germany

3. Division of Biochemical Toxicology, National Center for Toxicological Research/U.S. FDA, Jefferson, Arkansas 72079, United States

Funder

European Regional Development Fund

Univerzita Karlova v Praze

Grantov? Agentura, Univerzita Karlova

Faculty of Pharmacy in Hradec Kr?lov?, Charles University

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link